

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10528463
	Filing Date		2005-03-21
	First Named Inventor	Chantal GUILLEMETTE	
	Art Unit	1634	
	Examiner Name	Amanda Marie SHAW	
	Attorney Docket Number	6013-118US	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6395481		2002-05-28	Di Rienzo et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10528463
Filing Date	2005-03-21
First Named Inventor	Chantal GUILLEMETTE
Art Unit	1634
Examiner Name	Amanda Marie SHAW
Attorney Docket Number	6013-118US

1	GIRARD et al., Identification of common polymorphisms in the promoter of the UST1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver, Pharmacogenetics, 2004, Vol 14 No 8.	<input type="checkbox"/>
2	KUYPERS et al., The impact of uridine diphosphate - glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients, Clinical Pharmacology and Therapeutics, 2005;78(4):351-61.	<input type="checkbox"/>
3	HESSELINK et al., Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid, Clinical Pharmacology and Therapeutics, 2005;78:317-21.	<input type="checkbox"/>
4	ZAWISZA, FDA News, FDA Clears Genetic Test That Advances Personalized Medicine Test Helps Determine Safety of Drug Therapy, August 22, 2005. http://www.fda.gov/bbs/topics/NEWS/2005/NEW01220.html	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.